Accéder au contenu
MilliporeSigma
  • Butylated hydroxyanisole mechanistic data and risk assessment: conditional species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion.

Butylated hydroxyanisole mechanistic data and risk assessment: conditional species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion.

Pharmacology & therapeutics (1996-01-01)
J Whysner, G M Williams
RÉSUMÉ

Butylated hydroxyanisole (BHA), at high doses, has been found to induce forestomach squamous cell carcinomas in rodents, but not glandular cell or other types of neoplasms. BHA is not DNA-reactive, and the epigenetic mechanism of tumor formation involves cytotoxicity and enhanced cell proliferation, which are mostly reversible. Humans lack a forestomach and, therefore, are predicted to be much less sensitive than rodents to the effects of BHA. Also, the exposures to humans are well below doses producing the epigenetic effects in rodents. It has been concluded that BHA is an agent whose rodent carcinogenicity is conditionally species-specific and not relevant to humans.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Hydroxyanisole butylé, ≥98.5%
Sigma-Aldrich
Hydroxyanisole butylé, 99%, FCC, FG
Supelco
Hydroxyanisole butylé, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Hydroxyanisole butylé, analytical standard
Hydroxyanisole butylé, European Pharmacopoeia (EP) Reference Standard